ValuEngine upgraded shares of Medical Transcription Billing (NASDAQ:MTBC) from a sell rating to a hold rating in a research report released on Tuesday.
MTBC has been the subject of a number of other reports. Zacks Investment Research downgraded Medical Transcription Billing from a buy rating to a hold rating in a research note on Saturday, January 6th. Chardan Capital upped their price objective on Medical Transcription Billing from $2.25 to $2.75 and gave the stock a buy rating in a research note on Tuesday, November 14th.
Medical Transcription Billing (NASDAQ:MTBC) opened at $3.89 on Tuesday. The company has a market capitalization of $42.55, a price-to-earnings ratio of -3.70 and a beta of 1.98. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.15 and a current ratio of 1.15. Medical Transcription Billing has a 52 week low of $0.29 and a 52 week high of $5.44.
COPYRIGHT VIOLATION NOTICE: This story was originally reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another publication, it was stolen and republished in violation of United States & international trademark & copyright laws. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2018/02/21/medical-transcription-billing-mtbc-lifted-to-hold-at-valuengine.html.
About Medical Transcription Billing
Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Medical Transcription Billing Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing and related companies with MarketBeat.com's FREE daily email newsletter.